Related Experiment Videos
Captopril in essential hypertension
Insights
Captopril effectively manages essential hypertension, often with a diuretic. Doses of 150-300 mg are generally adequate for blood pressure control with minimal side effects.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Essential hypertension affects millions globally, necessitating effective and safe treatment options.
- Current antihypertensive therapies require ongoing evaluation for efficacy and tolerability.
Purpose of the Study:
- To assess the efficacy and tolerability of captopril in patients with essential hypertension.
- To determine optimal dosing strategies for captopril, with or without hydrochlorothiazide.
Main Methods:
- A study involving 41 patients with essential hypertension (stages I-III).
- Patients received captopril monotherapy or combination therapy with hydrochlorothiazide.
- Blood pressure response, plasma renin activity, and safety parameters were monitored.
Main Results:
- 42% of patients responded to captopril alone; 58% required a diuretic.
- No significant correlation was found between drug response and plasma renin activity.
- Captopril was well-tolerated, with mild, transient side effects reported in a few patients. No significant adverse effects on renal function or metabolic parameters were observed.
Conclusions:
- Captopril, at doses of 150-300 mg daily, is effective in controlling blood pressure in most essential hypertension patients.
- Combination therapy with hydrochlorothiazide may be necessary for a significant portion of patients.
- Captopril demonstrates a favorable safety profile for managing essential hypertension.
Abstract:
1 Forty-one patients with essential hypertension, stages I, II, and III, were treated with captopril alone or in combination with hydrochlorothiazide. Forty two percent were responsive to captopril alone, while the remaining 58% also required the diuretic. The need for the diuretic was related to the phase of hypertension. 2 There was no significant relation between drug response and plasma renin activity. Serum concentrations of creatinine and potassium remained normal, and there were no pathological changes in serum glucose, cholesterol, uric acid concentrations, erythrocyte count, packed cell volume, haemoglobin, or heart rate. 3 Captopril was well tolerated. One patient developed a rash and another ageusia, which disappeared spontaneously. A third, who was also taking allopurinol, developed leucopenia but it disappeared after treatment was withdrawn. There were no cases of proteinuria attributable to captopril; and proteinuria disappeared in four of five patients who were proteinurin before the start of treatment. 4 These findings suggest that doses of captopril of 150 mg to 300 mg (with or without a diuretic) may be adequate for controlling the blood pressure of most patients with essential hypertension.